Biotechnology

Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19

TAIPEI and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focused on human efficacy and innovation of first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its novel oral drug, Silmita...

2021-08-16 15:29 2179

GeneQuantum announces a key leadership appointment

SUZHOU, China, Aug. 15, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmacetucial company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced a key appointment to further strengt...

2021-08-16 10:00 1763

InxMed's IN10018 Receives U.S. FDA Fast Track Designation for the Treatment of Platinum-resistant Ovarian Cancer

NANJING, China, Aug. 15, 2021 /PRNewswire/ -- InxMed (Nanjing) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today the U.S. Food and Drug Administration (FDA) has granted Fas...

2021-08-16 09:31 1983

Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India

SHANGHAI, Aug. 15, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), to expand the ...

2021-08-16 08:00 8363

WuXi AppTec Reports Strong 2021 Interim Results

* Revenue Up 45.7% Year-Over-Year to RMB10,537 Million * Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million * Diluted EPS Up 46.8% Year-Over-Year to RMB0.91 * Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 67.8% Year-Over-...

2021-08-12 17:52 3947

NUHS Embarks on Holomedicine Research in Singapore, Using Mixed Reality Technology to Enhance Diagnosis, Education and Patient Care

SINGAPORE, Aug. 12, 2021 /PRNewswire/ -- To be able to literally "see inside" a patient's skull and identify the location of the tumour deep in the brain, right on the operating table, may no longer be science fiction with the help of a Mixed Reality (MR) headset.

2021-08-12 15:00 2541

ImmVira's MVR-T3011 IV Completed First Dosing for Intravenous Administration in a U.S. Phase I Clinical Trial

SHENZHEN, China, Aug. 10, 2021 /PRNewswire/ -- ImmVira announced that it has initiated its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011). The first patient has been dosed, receiving MVR-T3011 intravenous (IV) administration in the U.S. onAugust 10, 2021. The Phase I clin...

2021-08-11 10:45 1818

Belief Biomed's Gene Therapy for Hemophilia B Receives NMPA IND Approval: First Intravenous Infusion Gene Therapy for Rare Disease in China

SHANGHAI, Aug. 10, 2021 /PRNewswire/ -- On August 10th, 2021,Belief Biomed announced thatChina's National Medical Products Administration (NMPA) has cleared the IND (Investigational New Drug) application for Belief Biomed's BBM-H901. This marks the first IND approval for Intravenous (i.v.) infusi...

2021-08-10 23:39 3495

INDICAID(TM) COVID-19 Rapid Antigen Test Receives Emergency Use Authorization from the U.S. Food and Drug Administration

GARDEN GROVE, Calif., Aug. 10, 2021 /PRNewswire/ -- PHASE Scientific International LTD (PHASE Scientific), a high-growth biotech company founded by bioengineers fromUCLA, today announced that itsINDICAID™ COVID-19 Rapid Antigen Test (INDICAID) received Emergenc...

2021-08-10 22:00 2575

FibroBiologics Announces Inaugural Board of Directors

Company Announces Formation of Board of Directors HOUSTON, Aug. 6, 2021 /PRNewswire/ -- FibroBiologics, a clinical stage company developing fibroblast-based therapeutic solutions for chronic diseases, announced today the formation of its Board of Directors.  Leading this group is Chairman,Pete ...

2021-08-06 22:01 3210

ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody

* South Korea's MFDS clears IND application for a Phase 1 study evaluating the safety and preliminary efficacy of ABL501 as a monotherapy for solid tumor treatment * ABL's third IND this year for bispecific antibody therapeutics SEONGNAM, South Korea, Aug. 4, 2021 /PRNewswire/ -- ABL Bio, Inc...

2021-08-04 21:30 2711

Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's

MELBOURNE, Australia, Aug. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the United States Patent and Trademark Of...

2021-08-04 20:39 25553

Happiness Biotech Announced Financial Results for Fiscal Year Ended March 31, 2021

NANPING, China, Aug. 2, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer and e-commerce services provider, today announced its financial results for the fiscal year endedMarch 31, 2021. F...

2021-08-02 20:00 29417

Bionomics Announces Plans to Conduct U.S. Initial Public Offering

ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United ...

2021-08-02 18:00 14601

BIOKANGTAI COVID-19 Vaccine Approved for Phase III Clinical Trial in the Philippines

SHENZHEN, China, Aug. 2, 2021 /PRNewswire/ -- On July 30, Shenzhen Kangtai Biological Products Co., Ltd. (BIOKANGTAI) was approved by the Philippine Food and Drug Administration (PFDA) to launch the phase III clinical trial of its independently developed Inactivated COVID-19 Vaccine (Vero cells) ...

2021-08-02 15:25 6001

LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic

SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH). ...

2021-08-02 11:11 1881

Appendix 4C - Q4 FY21 Quarterly Cash Flow Report

Highlights: * Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial * Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein related neurodegeneration in MSA animal model * Presents to MST Access Australian Micro & Small Caps Conference ...

2021-07-30 21:05 15634

I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease

* Planning underway for a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid protein plaques in Alzheimer's Disease SHANGHAI and GAITHERSBURG, Md., July 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage bio...

2021-07-30 20:00 9322

Bon Natural Life Limited Breaks Ground on Its Third Production Facility in Yumen

XIAN, China, July 29, 2021 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solutions provider in the natural, health and personal care industries, officially broke ground today on its third production facility in Yumen City's Material Chem...

2021-07-29 21:00 13234

I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million

SHANGHAI and GAITHERSBURG, Md., July 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors (the "Board") has authorized...

2021-07-29 20:00 7819